Find Ivabradine Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Ivabradine Hydrochloride

Ivabradine Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

39 API Suppliers, 11 USDMF, 1 JDMF, 9 EU WC, 2 KDMF, 8 NDC API, 28 Listed Suppliers

DEVELOPMENTS

2 Drug(s) in Development

2 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

21 Suppliers

21 Suppliers

DOSSIERs // Finished Dosage Formulations

91 Dossiers, 11 FDA Orange Book, 39 Europe, 2 Canada, 4 Australia, 6 South Africa, 29 Listed Dossiers

RELATED EXCIPIENT COMPANIES

Suppliers, 26 Kerry, 13 Roquette, 10 Corel Pharma Chem, 8 Microlex e.U, 7 Seppic, 6 Lonza Capsugel, 5 Gangwal Healthcare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 SPI Pharma, 4 Ideal Cures Pvt Ltd, 4 Gangwal Chemicals, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Kima Chemical, 3 Sigachi Industries, 3 Actylis, 2 Ingredion Pharma Solutions, 2 Nanjing Well Pharmaceutical, 2 DFE Pharma, 2 The Dow Chemical Company, 1 Vasa Pharmachem, 1 ACG Worldwide, 1 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 1 Rochem International Inc

EXCIPIENTS BY APPLICATIONS

41 Fillers, Diluents & Binders, 40 Coating Systems & Additives, 17 Controlled & Modified Release, 14 Direct Compression, 11 Lubricants & Glidants, 8 Film Formers & Plasticizers, 8 Granulation, 8 Taste Masking, 6 Co-Processed Excipients, 5 Thickeners and Stabilizers, 5 Chewable & Orodispersible Aids, 5 Disintegrants & Superdisintegrants, 5 Empty Capsules, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Solubilizers, 3 Emulsifying Agents, 3 Parenteral, 2 Coloring Agents, 1 Topical, 1 Rheology Modifiers

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 23 Finished Drug Prices

MARKET PLACE

12 APIs, 3 DOSSIERS // FDF

PATENTS

20 US Patents, 2 US Exclusivities, 14 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 3 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 14 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

6,599

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

117.00

Annual Reports

FDF Market Place

EXCIPIENTS

117

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 148849-67-6, Ivabradine hcl, Procoralan, Corlentor, Corlanor, Ivabradine (hydrochloride)

Molecular Formula

C₂₇H₃₇ClN₂O₅

Molecular Weight

505.0 g/mol

InChI Key

HLUKNZUABFFNQS-ZMBIFBSDSA-N

FDA UNII

TP19837BZK

A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE.

1 2D Structure

Ivabradine Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;hydrochloride

2.1.2 InChI

InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1

2.1.3 InChI Key

HLUKNZUABFFNQS-ZMBIFBSDSA-N

2.1.4 Canonical SMILES

CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC.Cl

2.1.5 Isomeric SMILES

CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.Cl

2.2 Other Identifiers

2.2.1 UNII

TP19837BZK

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one

2. Corlanor

3. Ivabradine

4. S 16257

5. S 16257 2

6. S 16257-2

7. S 162572

8. S 16260 2

9. S 16260-2

10. S 162602

11. S-16257

12. S-16257-2

13. S-16260-2

14. S16257

15. S162572

16. S162602

2.3.2 Depositor-Supplied Synonyms

1. 148849-67-6

2. Ivabradine Hcl

3. Procoralan

4. Corlentor

5. Corlanor

6. Ivabradine (hydrochloride)

7. Tp19837bzk

8. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-benzo[d]azepin-2-one Hydrochloride

9. Ivabradine Hydrochloride [usan]

10. Chebi:85969

11. Amg 998

12. Amg-998

13. S-16257-2

14. 2h-3-benzazepin-2-one, 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)

15. Ncgc00181343-01

16. 148849-67-6 (hcl)

17. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride

18. 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride

19. Ivabradinehydrochloride

20. Ivabradine Hcl (procoralan)

21. S16257

22. Unii-tp19837bzk

23. Corlentor (tn)

24. Corlanor (tn)

25. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)

26. 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride

27. Coralan (tn)

28. Ivabrandine Hydrochloride

29. Ivabradine Monohydrochloride

30. Dsstox_cid_26913

31. Dsstox_rid_82011

32. Dsstox_gsid_46913

33. Schembl23470

34. Mls006010110

35. Ivabradine Hydrochloride- Bio-x

36. Chembl2145077

37. Dtxsid2046913

38. Hy-b0162a

39. 3-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one;hydrochloride

40. Bcp05218

41. Tox21_112802

42. Ac-543

43. Ivabradine Hydrochloride (jan/usan)

44. Ivabradine Hydrochloride [mi]

45. Mfcd00929899

46. S2086

47. Ivabradine Hydrochloride [jan]

48. Akos015849582

49. Akos016002249

50. Bcp9000798

51. Ccg-269739

52. Cs-1994

53. Gs-3584

54. Ivabradine Hydrochloride [who-dd]

55. (7,8-dimethoxy 3-(3-(((1s)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one Hydrochloride

56. (s)-3-(3-(((4,5-dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride

57. Bi164596

58. Smr004701246

59. Ivabradine Hydrochloride [ema Epar]

60. Ivabradine Hydrochloride, >=98% (hplc)

61. Am20090729

62. B1360

63. Cas-148849-67-6

64. I0847

65. Ivabradine Hydrochloride [orange Book]

66. D08095

67. 974i008

68. J-008523

69. J-521616

70. Q27158823

71. (+)-s16257

72. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride

73. 2h-3-benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride, (s)-

74. 3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one Hydrochloride

75. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride

76. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,

77. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one Hydrochloride

78. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one--hydrogen Chloride (1/1)

79. N-{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-n-methylpropan-1-aminium Chloride

2.4 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₃₇ClN₂O₅
Molecular Weight	505.0 g/mol
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	10
Exact Mass	504.2391000 g/mol
Monoisotopic Mass	504.2391000 g/mol
Topological Polar Surface Area	60.5 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	663
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

- in adults unable to tolerate or with a contra-indication to the use of beta-blockers

- in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

* Symptomatic treatment of chronic stable angina pectoris:

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

- in adults unable to tolerate or with a contraindication to the use of beta-blockers

- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

* Treatment of chronic heart failure:

Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Symptomatic treatment of chronic stable angina pectoris

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

- in adults unable to tolerate or with a contraindication to the use of beta-blockers

- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

Treatment of chronic heart failure

* Symptomatic treatment of chronic stable angina pectoris:

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm.

Ivabradine is indicated:

- in adults unable to tolerate or with a contra-indication to the use of beta-blockers

- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

* Treatment of chronic heart failure:

Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Treatment of angina pectoris, Treatment of chronic heart failure, Treatment of coronary artery disease

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Cardiovascular Agents

Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)

5.2 ATC Code

C01EB17

Market Place

Home

Post Enquiry

Market Place